Eagle Pharmaceuticals (EGRX) Reports In-Line Q4 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Eagle Pharmaceuticals (EGRX) Reports In-Line Q4 EPS

Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2017 Results

February 26, 2018 6:50 AM EST

-- Record 2017 revenue of $237 million

--Q4 2017 net income of $0.58 per diluted share and Adjusted Non-GAAP net income of $1.00 per diluted share --

-- FY 2017 net income of $3.27 per diluted share and Adjusted Non-GAAP net income of $4.34 per diluted share --

-- Agreed on path forward with the FDA for an additional clinical trial for RYANODEX for Exertional Heat Stroke --

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (Eagle or the Company) (Nasdaq: EGRX) today announced its financial results for the... More